Clinical Trials Directory

Trials / Completed

CompletedNCT02962830

Sufentanil Pharmacokinetics After Intra Amniotic Injection

Assessment of Fetal and Maternal Sufentanil Pharmacokinetics After Intra-amniotic Injection

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
8 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The fetus may be exposed during pregnancy to nociceptive stimuli because of fetal pathology (e.g., malformation) or a diagnostic or therapeutic procedure. To date, there is very little data and no consensus on fetal analgesia. The aim of the investigators study is to evaluate the pharmacokinetics of Sufentanil after intra amniotic injection.

Conditions

Interventions

TypeNameDescription
DRUGSufentanilintra-amniotic injection of 10 micrograms of Sufentanil

Timeline

Start date
2017-04-19
Primary completion
2024-05-28
Completion
2024-05-29
First posted
2016-11-11
Last updated
2025-12-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02962830. Inclusion in this directory is not an endorsement.